Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2016

20.06.2016

Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction

verfasst von: Sean van Diepen, Wendimagegn G. Alemayehu, Yinggan Zheng, Pierre Theroux, L. Kristin Newby, Kenneth W. Mahaffey, Christopher B. Granger, Paul W. Armstrong

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Coronary plaque rupture mediating acute ST segment elevation myocardial infarction (STEMI) is associated with a systemic inflammatory response. Whether early temporal changes in inflammatory biomarkers are associated with angiographic and electrocardiographic markers of reperfusion and subsequent clinical outcomes is unclear. In the APEX-AMI biomarker substudy, 376 patients with STEMI had inflammatory biomarkers measured at the time of hospital presentation and 24 h later. The primary outcome was the 90-day composite of death, shock, or heart failure. Secondary reperfusion outcomes were (1) worst least residual ST segment elevation (ST-E: <1 mm, 1 to <2 mm, ≥2 mm) and (2) post-percutaneous coronary intervention (PCI) TIMI flow grade (0/1/2 vs 3) and TIMI myocardial perfusion grade (TMPG 0/1 vs 2/3). The 90-day incidence of death, shock or heart failure was 21.3 % in this cohort. Electrocardiographic reperfusion (worst residual ST-E <1 mm, 1 to <2 mm, ≥2 mm) was associated with differences in 24 h change in N-terminal proB-type natriuretic peptide (NT-proBNP) (1192.8, 1332.5, 1859.0 ng/mL; p = 0.043) and the pro-inflammatory cytokines Interleukin (IL)-6 (14.0, 13.6, 22.1 pg/mL; p = 0.016), IL-12 (−0.5, −0.9, −0.1 pg/mL; p = 0.013), and tumor necrosis factor α (TNFα) (1.0, 0.6, 3.6 pg/mL; p = 0.023). Angiographic reperfusion (TMPG 0/1 vs 2/3) was associated with changes in median NT-proBNP (2649.3, 1382.7 ng/mL; p = 0.002) and IL-6 (28.7, 15.1; p = 0.040). After adjustment for baseline covariates, the 24 h change in the pro-inflammatory cytokine TNFα [hazard ratio (HR) 0.49; 95 % CI 0.26–0.95; p = 0.035] and the anti-inflammatory cytokine IL 10 (HR 1.41; 95 % CI 1.06–1.87; p = 0.018) were independently associated with the primary composite outcome. Successful coronary reperfusion was associated with less systemic inflammatory response and greater temporal inflammatory changes were independently associated with higher 90-day composite of death, shock, or heart failure. These findings provide support for an association between success of reperfusion, an acute STEMI inflammatory response and subsequent clinical outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Morishima I, Sone T, Okumura K et al (2000) Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36(4):1202–1209PubMedCrossRef Morishima I, Sone T, Okumura K et al (2000) Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36(4):1202–1209PubMedCrossRef
2.
Zurück zum Zitat Buller CE, Fu Y, Mahaffey KW et al (2008) ST segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 118(13):1335–1346PubMedCrossRef Buller CE, Fu Y, Mahaffey KW et al (2008) ST segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 118(13):1335–1346PubMedCrossRef
3.
Zurück zum Zitat Grabowski M, Filipiak KJ, Malek LA et al (2007) Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 115(3):386–390PubMedCrossRef Grabowski M, Filipiak KJ, Malek LA et al (2007) Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 115(3):386–390PubMedCrossRef
4.
Zurück zum Zitat Ezekowitz JA, Theroux P, Chang W et al (2006) N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol 22(5):393–397PubMedPubMedCentralCrossRef Ezekowitz JA, Theroux P, Chang W et al (2006) N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol 22(5):393–397PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Mega JL, Morrow DA, De Lemos JA et al (2004) B-type natriuretic peptide at presentation and prognosis in patients with ST segment elevation myocardial infarction: an entire-TIMI-23 substudy. J Am Coll Cardiol 44(2):335–339PubMedCrossRef Mega JL, Morrow DA, De Lemos JA et al (2004) B-type natriuretic peptide at presentation and prognosis in patients with ST segment elevation myocardial infarction: an entire-TIMI-23 substudy. J Am Coll Cardiol 44(2):335–339PubMedCrossRef
6.
Zurück zum Zitat Damman P, Beijk MAM, Kuijt WJ et al (2011) Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. J Am Coll Cardiol 57(1):29–36PubMedCrossRef Damman P, Beijk MAM, Kuijt WJ et al (2011) Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. J Am Coll Cardiol 57(1):29–36PubMedCrossRef
7.
Zurück zum Zitat van Diepen S, Newby LK, Lopes RD et al (2013) Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol 168(3):2127–2133PubMedCrossRef van Diepen S, Newby LK, Lopes RD et al (2013) Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol 168(3):2127–2133PubMedCrossRef
8.
Zurück zum Zitat Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF (2004) Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 4(2):166–170PubMedCrossRef Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF (2004) Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 4(2):166–170PubMedCrossRef
9.
Zurück zum Zitat Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94(12):1543–1553PubMedCrossRef Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94(12):1543–1553PubMedCrossRef
10.
Zurück zum Zitat Herskowitz A, Choi S, Ansari AA, Wesselingh S (1995) Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 146(2):419–428PubMedPubMedCentral Herskowitz A, Choi S, Ansari AA, Wesselingh S (1995) Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 146(2):419–428PubMedPubMedCentral
11.
Zurück zum Zitat Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC (2001) Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104(7):746–749CrossRef Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC (2001) Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104(7):746–749CrossRef
12.
Zurück zum Zitat The Apex-AMI Investigators (2007) Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 297(1):43–51CrossRef The Apex-AMI Investigators (2007) Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 297(1):43–51CrossRef
13.
Zurück zum Zitat Mahaffey KW, Reist CJ, Fu Y et al (2008) Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. Contemp Clini Trials 29(6):887–895CrossRef Mahaffey KW, Reist CJ, Fu Y et al (2008) Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. Contemp Clini Trials 29(6):887–895CrossRef
14.
Zurück zum Zitat Armstrong PW, Adams PX, Al-Khalidi HR et al (2005) Assessment of pexelizumab in acute myocardial infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149(3):402–407PubMedCrossRef Armstrong PW, Adams PX, Al-Khalidi HR et al (2005) Assessment of pexelizumab in acute myocardial infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149(3):402–407PubMedCrossRef
15.
Zurück zum Zitat van Diepen S, Roe M, Lopes R et al (2012) Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis 34(1):106–113PubMedCrossRef van Diepen S, Roe M, Lopes R et al (2012) Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis 34(1):106–113PubMedCrossRef
16.
Zurück zum Zitat Brener SJ, Moliterno DJ, Aylward PE et al (2008) Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. Eur Heart J 29(9):1127–1135PubMedCrossRef Brener SJ, Moliterno DJ, Aylward PE et al (2008) Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. Eur Heart J 29(9):1127–1135PubMedCrossRef
17.
Zurück zum Zitat Koten K, Hirohata S, Miyoshi T et al (2008) Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin Biochem 41(1–2):30–37PubMedCrossRef Koten K, Hirohata S, Miyoshi T et al (2008) Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin Biochem 41(1–2):30–37PubMedCrossRef
18.
Zurück zum Zitat Patti G, Mega S, Pasceri V et al (2005) Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol 28(4):193–196PubMedCrossRef Patti G, Mega S, Pasceri V et al (2005) Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol 28(4):193–196PubMedCrossRef
19.
Zurück zum Zitat Westerhout CM, Pieper KS, James SK et al (2013) Dynamic modeling of 90-day mortality in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Am Heart J 165(3):354–362PubMedCrossRef Westerhout CM, Pieper KS, James SK et al (2013) Dynamic modeling of 90-day mortality in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Am Heart J 165(3):354–362PubMedCrossRef
20.
Zurück zum Zitat Biasucci LM, Liuzzo G, Fantuzzi G et al (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99(16):2079–2084PubMedCrossRef Biasucci LM, Liuzzo G, Fantuzzi G et al (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99(16):2079–2084PubMedCrossRef
21.
Zurück zum Zitat Heeschen C, Dimmeler S, Hamm CW et al (2003) Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107(16):2109–2114PubMedCrossRef Heeschen C, Dimmeler S, Hamm CW et al (2003) Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107(16):2109–2114PubMedCrossRef
22.
Zurück zum Zitat Lee KW, Lip GYH, Tayebjee M, Foster W, Blann AD (2005) Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105(2):526–532PubMedCrossRef Lee KW, Lip GYH, Tayebjee M, Foster W, Blann AD (2005) Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105(2):526–532PubMedCrossRef
23.
Zurück zum Zitat Deten A, Volz HC, Briest W, Zimmer H-G (2002) Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction experimental studies in rats. Cardiovasc Res 55(2):329–340PubMedCrossRef Deten A, Volz HC, Briest W, Zimmer H-G (2002) Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction experimental studies in rats. Cardiovasc Res 55(2):329–340PubMedCrossRef
24.
Zurück zum Zitat Irwin MW, Mak S, Mann DL et al (1999) Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 99(11):1492–1498PubMedCrossRef Irwin MW, Mak S, Mann DL et al (1999) Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 99(11):1492–1498PubMedCrossRef
25.
Zurück zum Zitat Uyemura K, Demer LL, Castle SC et al (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97(9):2130–2138PubMedPubMedCentralCrossRef Uyemura K, Demer LL, Castle SC et al (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97(9):2130–2138PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Hauer AD, Uyttenhove C, de Vos P et al (2005) Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112(7):1054–1062PubMedCrossRef Hauer AD, Uyttenhove C, de Vos P et al (2005) Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112(7):1054–1062PubMedCrossRef
27.
Zurück zum Zitat Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101(18):2149–2153PubMedCrossRef Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101(18):2149–2153PubMedCrossRef
28.
Zurück zum Zitat Valgimigli M, Ceconi C, Malagutti P et al (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation 111(7):863–870PubMedCrossRef Valgimigli M, Ceconi C, Malagutti P et al (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation 111(7):863–870PubMedCrossRef
29.
Zurück zum Zitat Puhakka M, Magga J, Hietakorpi S et al (2003) Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Cardiac Fail 9(4):325–332CrossRef Puhakka M, Magga J, Hietakorpi S et al (2003) Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Cardiac Fail 9(4):325–332CrossRef
30.
Zurück zum Zitat Szkodzinski J, Hudzik B, Osuch M et al (2011) Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart Vessels 26(4):399–407PubMedCrossRef Szkodzinski J, Hudzik B, Osuch M et al (2011) Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart Vessels 26(4):399–407PubMedCrossRef
31.
Zurück zum Zitat Frangogiannis NG, Mendoza LH, Lindsey ML et al (2000) IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 165(5):2798–2808PubMedCrossRef Frangogiannis NG, Mendoza LH, Lindsey ML et al (2000) IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 165(5):2798–2808PubMedCrossRef
32.
Zurück zum Zitat Frangogiannis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53(1):31–47PubMedCrossRef Frangogiannis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53(1):31–47PubMedCrossRef
33.
Zurück zum Zitat Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (1995) IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96(5):2304–2310PubMedPubMedCentralCrossRef Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (1995) IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96(5):2304–2310PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Chalikias GK, Tziakas DN, Kaski JC et al (2005) Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 182(1):135–143PubMedCrossRef Chalikias GK, Tziakas DN, Kaski JC et al (2005) Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 182(1):135–143PubMedCrossRef
35.
Zurück zum Zitat Kilic T, Ural D, Ural E et al (2006) Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 92(8):1041–1046PubMedPubMedCentralCrossRef Kilic T, Ural D, Ural E et al (2006) Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 92(8):1041–1046PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Waehre T, Halvorsen B, Damas JK et al (2002) Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 32(11):803–810PubMedCrossRef Waehre T, Halvorsen B, Damas JK et al (2002) Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 32(11):803–810PubMedCrossRef
37.
Zurück zum Zitat Woods A, Brull DJ, Humphries SE, Montgomery HE (2000) Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 21(19):1574–1583PubMedCrossRef Woods A, Brull DJ, Humphries SE, Montgomery HE (2000) Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 21(19):1574–1583PubMedCrossRef
38.
Zurück zum Zitat Jacobs M, Staufenberger S, Gergs U et al (1999) Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts. J Mol Cell Cardiol 31(11):1949–1959PubMedCrossRef Jacobs M, Staufenberger S, Gergs U et al (1999) Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts. J Mol Cell Cardiol 31(11):1949–1959PubMedCrossRef
39.
Zurück zum Zitat Kurrelmeyer KM, Michael LH, Baumgarten G et al (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97(10):5456–5461PubMedPubMedCentralCrossRef Kurrelmeyer KM, Michael LH, Baumgarten G et al (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97(10):5456–5461PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286(14):1754–1758PubMedCrossRef Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286(14):1754–1758PubMedCrossRef
41.
Zurück zum Zitat Martel C, Granger CB, Ghitescu M et al (2012) Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 164(1):43–51PubMedCrossRef Martel C, Granger CB, Ghitescu M et al (2012) Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 164(1):43–51PubMedCrossRef
Metadaten
Titel
Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction
verfasst von
Sean van Diepen
Wendimagegn G. Alemayehu
Yinggan Zheng
Pierre Theroux
L. Kristin Newby
Kenneth W. Mahaffey
Christopher B. Granger
Paul W. Armstrong
Publikationsdatum
20.06.2016
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1390-z

Weitere Artikel der Ausgabe 3/2016

Journal of Thrombosis and Thrombolysis 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.